New drug cocktail tried for Life-Threatening transplant complication
NCT ID NCT01453140
First seen Apr 14, 2026 · Last updated Jun 10, 2026 · Updated 11 times
Summary
This study tested a combination of drugs (cyclophosphamide, sirolimus, and sometimes azacitidine) to control severe graft-versus-host disease (GVHD) in people who had a stem cell transplant and did not respond to steroids. The goal was to boost the body's own regulatory T cells to calm the immune attack. Only 3 people enrolled before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT-VERSUS-HOST-DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Conditions
Explore the condition pages connected to this study.